This is a working overview of GLP-1 receptor, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-01-22 and is reviewed periodically as new material appears.
Tirzepatide is a synthetic linear peptide of 39 amino acids that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Its sequence derives from native GIP but incorporates non-natural residues and a C20 fatty diacid moiety linked to a lysine side chain. The lipophilic chain promotes albumin binding, which slows renal clearance and extends circulation time. The unmodified peptide has a molecular formula of C225H348N48O68 and a molecular mass near 4,813 daltons.
Receptor activation by tirzepatide raises intracellular cyclic AMP through Gs-coupled signalling at both targets. At the GLP-1 receptor the downstream effect includes glucose-dependent insulin release, suppressed glucagon secretion, delayed gastric emptying, and reduced appetite signalling in the hypothalamus. GIP receptor engagement adds insulinotropic activity and appears to influence lipid handling in adipose tissue. Because both receptors are stimulated at the same time, the pharmacological profile differs from that of selective GLP-1 receptor agonists, and the relative contribution of each arm remains an area of active investigation.
Clinical development proceeded through large phase 3 programmes in type 2 diabetes and in obesity or overweight with at least one weight-related comorbidity. Regulatory approvals followed in several jurisdictions for both indications. Weekly subcutaneous dosing reflects an elimination half-life of roughly five days. Open questions include the durability of metabolic effects after treatment stops, long-term cardiovascular and hepatic outcomes beyond completed trials, and whether the dual mechanism confers benefits independent of total receptor occupancy. Published literature continues to expand on these points. Substantial uncertainty remains about interindividual variability in response.
Tirzepatide is a synthetic peptide of 39 amino acids engineered from the native glucose-dependent insulinotropic polypeptide sequence. Its structure incorporates several non-natural residues and a C-terminal segment derived from glucagon-like peptide-1, together with a C20 fatty diacid moiety attached through a linker. The lipophilic side chain promotes binding to serum albumin, which slows renal clearance after administration. The compound is classified as a dual incretin receptor agonist and is supplied as a lyophilized powder for reconstitution or as a preformulated solution, depending on the presentation.
The peptide activates two G protein-coupled receptors, GIPR and GLP-1R. Binding triggers adenylyl cyclase activity and raises intracellular cyclic AMP in pancreatic beta cells, which potentiates insulin release when glucose is elevated. Signaling in the central nervous system is associated with reduced appetite and lower energy intake, while effects on gastric emptying and glucagon secretion are also reported. Because activity at both receptors is retained, the pharmacological profile is often described as incretin-based rather than selective for a single receptor.
After subcutaneous injection, absorption is gradual, and peak plasma levels are generally reached within one to three days. Albumin binding extends the apparent half-life to roughly five days, which supports a weekly administration schedule. Metabolism proceeds mainly through proteolytic cleavage of the peptide backbone and beta-oxidation of the fatty acid chain, rather than through cytochrome P450 pathways. Eliminated fragments are largely recycled through general protein turnover, and excretion of intact drug in urine is minimal. These properties distinguish the molecule from short-acting incretin mimetics.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | Unmodified peptide backbone |
| Molecular mass | approx. 4,813 Da | 39-residue linear chain |
| Receptor targets | GIP and GLP-1 | Dual agonist activity |
| Route | Subcutaneous injection | Weekly administration interval |
| Elimination half-life | approx. 5 days | Supports weekly dosing schedule |
Peptide active ingredients of this type are typically supplied as lyophilized powder because the dry form resists hydrolysis during transport. The material is hygroscopic, so vials are usually equilibrated to room temperature before opening to avoid condensation on the solid. Repeated freeze-thaw cycles can promote aggregation and are generally avoided by aliquoting stock into single-use portions. Personnel handling the powder work in controlled environments to limit inhalation of fine particles. Written procedures usually specify these steps rather than leaving them to individual judgment.
Long-term storage of the solid generally relies on temperatures at or below minus twenty degrees Celsius, while short-term working stocks may be held refrigerated. Light exposure is limited because photodegradation can alter side chains over extended periods. Solutions prepared for analysis are less stable than the dry powder and are typically used within the same working day. Buffer choice matters, since some aqueous conditions favor deamidation or oxidation at specific residues. Stability data are usually generated under defined accelerated conditions and then extrapolated with stated assumptions.
The molecule is a synthetic 39-amino-acid peptide whose backbone derives from the sequence of human glucose-dependent insulinotropic polypeptide, with several substitutions that raise metabolic stability and shift receptor preference. A C20 fatty diacid is attached through a short linker to a lysine side chain, a modification that increases binding to serum albumin. The reported monoisotopic mass is approximately 4813 Da. Near neutral pH the peptide carries a net negative charge, and the lipid tail makes the molecule markedly more hydrophobic than the unmodified parent sequence.
Dual agonism at the GIP and GLP-1 receptors underlies the observed pharmacology. Activation of GLP-1 receptors raises glucose-dependent insulin release, lowers glucagon secretion, slows gastric emptying and reduces appetite. GIP receptor activation contributes additional effects on adipose tissue and on energy balance, and the combined action on appetite appears larger than either pathway alone in animal models. Signalling bias and the relative contribution of each receptor arm to weight-related effects remain areas of active investigation.
Protons are spin-1/2 fermions and are composed of three valence quarks, making them baryons (a sub-type of hadrons). The two up quarks and one down quark of a proton are held together by the strong force, mediated by gluons. A modern perspective has a proton composed of the valence quarks (up, up, down), the gluons, and transitory pairs of sea quarks. Protons have a positive charge distribution, which decays approximately exponentially, with a root mean square charge radius of about 0.8 fm. Protons and neutrons are both nucleons, which may be bound together by the nuclear force to form atomic nuclei. The nucleus of the most common isotope of the hydrogen atom (with the chemical symbol "H") is a lone proton. The nuclei of the heavy hydrogen isotopes deuterium and tritium contain one proton bound to one and two neutrons, respectively. All other types of atomic nuclei are composed of two or more protons and various numbers of neutrons.
She has given a great deal of thought to how women are taught to act as they grow up and how that may impact their career decisions. In an interview in 2004, Osborn said, "In deciding whether to accept new challenges a remark by Diane Britten some years ago in The Times has proved very helpful: "When asked to do something women tend to say `Why me?' Men say `Why not me?' I have learned to say `Why not me?''' Summing up her advice to those in charge of sciences in universities and industry, she said in 2012, "Above all one has to get the argument across that it is wasteful, expensive and unfair to educate and train large numbers of woman scientists and then not use their talents in the job market or provide equal access to the top jobs."
=== In high-temperature processes === PVDF is used as piping, sheet, and internal coatings in high-temperature, hot acid, radiation environment applications due to PVDF's resistance characteristics and upper temperature thresholds. As piping, PVDF is rated up to 248 °F (120 °C). Examples of PVDF uses include nuclear reactor waste handling, chemical synthesis and production, (sulfuric acid, common), air plenums, and boiler service pipe.
Sources: en.wikipedia.org
==== Announcement ==== In mid-March 1989, both research teams were ready to publish their findings, and Fleischmann and Jones had agreed to meet at an airport on 24 March to send their papers to Nature via FedEx. Fleischmann and Pons, however, pressured by the University of Utah, which wanted to establish priority on the discovery, broke their apparent agreement, disclosing their work at a press conference on 23 March (they claimed in the press release that it would be published in Nature but instead submitted their paper to the Journal of Electroanalytical Chemistry). Jones, upset, faxed in his paper to Nature after the press conference. Fleischmann and Pons' announcement drew wide media attention, as well as attention from the scientific community. The 1986 discovery of high-temperature superconductivity had made scientists more open to revelations of unexpected but potentially momentous scientific results that could be replicated reliably even if they could not be explained by established theories. Many scientists were also reminded of the Mössbauer effect, a process involving nuclear transitions in a solid. Its discovery 30 years earlier had also been unexpected, though it was quickly replicated and explained within the existing physics framework.
However, it is provided in a tough fibreboard carton rather than in individual unitised polyethylene bags. It is a group feeding solution, and it is impractical to use on an individual basis for main meals. There are a multiple of group-sized retort pouches – 500 gram as opposed to 250 gram, several of which are required to be heated in order to provide a complete meal. Examples include Beef & Blackbean Sauce, Chicken Satay. Common elements include rice and vegetables such as corn, potatoes and carrots. The accessories such as snacks are consumable and can be carried individually. There are five menu choices, and each Combat Ration Five Man weighs around 10 kg (22 lb). Patrol Ration One Man is a complete 24-hour ration pack that contains freeze dried main meals, meaning that the total weight of each pack is reduced, however a correspondingly higher quantity of water must be carried in order to reconstitute the main meal. Otherwise, it is similar to the Combat Ration One Man. It is packed in tough clear polyethylene bags and is available in five menu choices.
=== South American Jaguars === The Jaguars consisted mainly of Argentine rugby players, but also with some from Uruguay, Brazil, Paraguay, Chile and Spain. While many of these countries suffered from dictatorships, they too had sporting bans of a sort. The Jaguars were not officially recognised by Union Argentina de Rugby, a stratagem to elude the prohibition of the Argentine government that since the early 1970s forbade any official relationship between any Argentine sport federation and South African and Rhodesian ones, due to the politics of those countries. This ostracism started in 1971 when the Argentine government forbade the Pumas to play a match in Rhodesia during the tour in South Africa.
Sources: en.wikipedia.org
It is a dual GIP and GLP-1 receptor agonist, frequently grouped with incretin-based peptide therapeutics. It is a peptide rather than a small molecule and is given by subcutaneous injection.
Selective agents engage only the GLP-1 receptor, whereas tirzepatide activates GIP and GLP-1 receptors simultaneously. This difference in receptor coverage is the principal pharmacological distinction emphasised in comparative reviews.
Downstream signalling is partly characterised, but the quantitative contribution of GIP versus GLP-1 receptor activation to metabolic outcomes is not settled. Review articles commonly flag this as an unresolved question rather than a settled finding.
It is a synthetic linear peptide that acts as a dual agonist at the GIP and GLP-1 receptors. It combines a modified incretin backbone with a fatty diacid side chain that extends its circulation time. It is not a small-molecule drug and is not orally absorbed in its native form.